We have discovered an incredibly unique stem cell firm, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the street. As BRTX prepares for its Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar currently, but that could all change in the blink of an eye. BRTX presents an incredible opportunity to investors that will have discovered the company before BRTX starts its phase 2 clinical trial using BRTX-100. The company recently announced that the Journal of Translational Medicine has published the results of the company’s study evaluating the benefits of long-term hypoxic culturing of human bone marrow-derived mesenchymal stem cells, which are used in the company’s BRTX-100 product.
The sector has picked back up and wise investors have been making bank playing the growth opportunities. Here are a few you should look at right now: BioRestorative Therapies, Inc. (BRTX), Insys Therapeutics, Inc. (INSY), and WEED Inc. (BUDZ).
BioRestorative Therapies, Inc. (BRTX)
Market Cap: $14.48M Share Price: $1.97
BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Journal of Translational Medicine has published the results of the Company’s study evaluating the benefits of long-term hypoxic (low oxygen) culturing of human bone marrow-derived mesenchymal stem cells (cells used in the Company’s product, BRTX-100). The study demonstrated that, as compared to cells cultured under normal atmospheric conditions (“normoxic”), hypoxic culturing improves mesenchymal stem cell properties and positively influences whole genome expression profiles with respect to the development of cellular therapies targeting the microenvironment of the intervertebral disc.
The FDA has authorized BioRestorative to commence a Phase 2 clinical trial using hypoxic cultured bone marrow-derived mesenchymal stem cells in its lead candidate, BRTX-100, to treat chronic degenerative disc disease.
The stock has pulled back after a large move, and looks like it may be a great opportunity for investors looking to catch a bottom.
Insys Therapeutics, Inc. (INSY)
Market Cap: $694.2M Share Price: $9.35
Insys Therapeutics, Inc announced the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys’ treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain. Despite the news the stock has maintained investor interest. Investors believe the company will bounce back.
WEED, Inc. (BUDZ)
Market Cap: $353.0M Share Price: $3.40
WEED, Inc. (BUDZ) is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. The company has made huge strides this week for shareholders.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and thirteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States